Corvus Pharmaceuticals Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 6,831,828 shares of Common Stock issuable upon exercise of warrants, representing 7.5% of the class. This percentage is calculated using March 12, 2026 outstanding shares of 83,992,407 and assumes exercise of the warrants.
The filing states the shared voting and dispositive power over the 6,831,828 warrant-issuable shares and attaches a Joint Filing Agreement as Exhibit 99.1.
Positive
None.
Negative
None.
Insights
Filing discloses warrant-based beneficial ownership and Rule 13d-1(k) joint filing.
The statement reports 6,831,828 shares issuable upon exercise of warrants and calculates a 7.5% stake using March 12, 2026 outstanding shares of 83,992,407. The filing is made under the joint-filing framework of Rule 13d-1(k).
Relevant dependencies include the actual exercise of warrants and any changes to outstanding shares; future filings would show conversion/exercise outcomes and voting changes.
Schedule 13G signals passive ownership from warrants rather than an active control campaign.
The report attributes shared voting and dispositive power over 6,831,828 shares issuable on warrant exercise and states a 7.5% percent of the class assuming exercise. The Joint Filing Agreement is attached as Exhibit 99.1.
Material changes would arise if warrants are exercised or additional filings amend ownership; timing and exercise decisions will determine actual shareholding and voting influence.
Key Figures
Warrant-issuable shares:6,831,828 sharesPercent of class:7.5%Shares outstanding used:83,992,407 shares
3 metrics
Warrant-issuable shares6,831,828 sharesIssuable upon exercise of warrants held by Sirenia fund/account
Percent of class7.5%Calculated assuming exercise using outstanding shares as of March 12, 2026
Shares outstanding used83,992,407 sharesOutstanding Common Stock as of March 12, 2026 (source: Form 10-K)
Key Terms
warrants, shared dispositive power, Schedule 13G
3 terms
warrantsfinancial
"The 6,831,828 shares of Common Stock are issuable upon exercise of warrants."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
shared dispositive powerregulatory
"Shared Dispositive Power 6,831,828.00"
Schedule 13Gregulatory
"This statement is filed by: Sirenia Capital Management LP ... under Rule 13d-1(k)."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Corvus Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
221015100
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
221015100
1
Names of Reporting Persons
Sirenia Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,831,828.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,831,828.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,831,828.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.5 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: The 6,831,828 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants.
SCHEDULE 13G
CUSIP Number(s):
221015100
1
Names of Reporting Persons
Alex Silverstein
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,831,828.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,831,828.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,831,828.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.5 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The 6,831,828 shares of Common Stock are issuable upon exercise of warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Corvus Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
901 Gateway Boulevard, Third Floor, South San Francisco, California 94080
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Corvus Pharmaceuticals, Inc. (the "Issuer") issuable upon exercise of warrants held by an investment fund (the "Sirenia Fund") and managed account (the "Sirenia Account") it manages; and
(ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock issuable upon exercise of warrants held by the Sirenia Fund and Sirenia Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)
Citizenship:
Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
221015100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 83,992,407 shares of Common Stock outstanding as of March 12, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 12, 2026, and assumes the exercise of the warrants held by the Sirenia Fund and Sirenia Account.
(b)
Percent of class:
7.5%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sirenia Capital Management LP
Signature:
/s/ Kolby Loft
Name/Title:
Kolby Loft, General Counsel & Chief Compliance Officer
What does the Schedule 13G filed by Sirenia Capital for CRVS disclose?
It discloses beneficial ownership of 6,831,828 shares issuable upon exercise of warrants, representing 7.5% of the class calculated using March 12, 2026 outstanding shares of 83,992,407 and assuming exercise of the warrants.
How was the 7.5% ownership percentage for CRVS calculated?
The 7.5% figure uses an aggregate share count of 83,992,407 Common Stock outstanding as of March 12, 2026, and assumes the exercise of the 6,831,828 warrants held by the Sirenia Fund and Sirenia Account.
Who are the reporting persons named in the CRVS filing?
The filing is made jointly by Sirenia Capital Management LP and Alex Silverstein, the managing member of the general partner, pursuant to a Joint Filing Agreement filed as Exhibit 99.1 on the Schedule 13G.
Do the reported shares represent currently outstanding CRVS shares?
No; the 6,831,828 shares are described as issuable upon exercise of warrants. The filing’s percentage calculation assumes exercise and uses outstanding shares as of March 12, 2026 for the denominator.
